Active atopic dermatitis or skin condition that disrupts the epidermis
Subject, or subject’s close household contacts (defined as those who share housing or have close physical contact) have any of the following conditions during the screening and/or treatment periods:\r\n* Active or a history of atopic dermatitis, eczema or other eczematoid skin disorders that disrupt the epidermis\r\n* Other acute, chronic or exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne or other open rashes or wounds) until condition resolves\r\n* Pregnant or nursing\r\n* Immunodeficient or immunosuppressed (by disease or therapy), including human immunodeficiency virus (HIV) infection
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
The recombinant vaccinia vaccine should not be administered if the following apply to either recipients or, for at least 3 weeks after vaccination, their close household contacts (close household contacts are those who share housing or have close physical contact):\r\n* Persons with active or a history of eczema or other eczematoid skin disorders\r\n* Those with other acute, chronic or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster, severe acne or other open rashes or wounds) until condition resolves\r\n* Pregnant or nursing women; children under 3 years of age
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
Subject with current skin diseases that the investigator feels is not safe for study participation including but not limited to severe atopic dermatitis, cutaneous T-cell lymphoma, erythroderma
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects must be aged 2-50 years
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects must be co-enrolled in NIH protocol 08-HG-0059
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects must have a diagnosis of atopic dermatitis on the basis of the criteria defined by UK Working Party's Diagnostic Criteria for Atopic Dermatitis
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects must have a primary care provider
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects must have an Objective SCORAD (SCORing Atopic Dermatitis) of >= 15 indicating AD severity of moderate to severe
COHORT 3: ATOPIC DERMATITIS PATIENTS: Prior to initiation of randomized treatment, subjects must have signs of bacterial skin infections (skin weeping, crusting, and/or pustules)
COHORT 3: ATOPIC DERMATITIS PATIENTS: Access to bathing facilities
COHORT 3: ATOPIC DERMATITIS PATIENTS: All subjects and/or their legally authorized representative (LAR) must have the ability and agree to participate fully and comply with the procedures of the protocol and provide informed consent; pediatric patients will be included in age appropriate discussions and age appropriate assent will be obtained in accordance with NIH guidelines
COHORT 3: ATOPIC DERMATITIS PATIENTS: Does not meet inclusion criteria
COHORT 3: ATOPIC DERMATITIS PATIENTS: Any female with symptoms and/or serum hormone levels consistent with perimenopause
COHORT 3: ATOPIC DERMATITIS PATIENTS: Known allergic reaction to beta-lactam class drugs, lidocaine, or epinephrine
COHORT 3: ATOPIC DERMATITIS PATIENTS: Family history of toxic epidermal necrolysis
COHORT 3: ATOPIC DERMATITIS PATIENTS: Known allergic reaction to sodium hypochlorite (NaOCl)
COHORT 3: ATOPIC DERMATITIS PATIENTS: Use of systemic antibiotics within 8 weeks, or topical antibiotics on intended sampling sites within 3 weeks, prior to baseline sampling
COHORT 3: ATOPIC DERMATITIS PATIENTS: Use of topical corticosteroids on all intended sampling sites within 7 days, prior to baseline sampling
COHORT 3: ATOPIC DERMATITIS PATIENTS: Use of topical or oral CAM agents within 4 weeks of initiation of treatment
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects with known primary or acquired immunodeficiency
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects with unstable or uncontrolled medical conditions that could require hospitalization during the initial month of the study or who have been hospitalized for treatment of these conditions in the one month prior to baseline sampling
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants within 7 days or 5 half-lives (whichever is the longer time period) of initiating treatment on this protocol
COHORT 3: ATOPIC DERMATITIS PATIENTS: Subjects who are currently receiving or have received chemotherapy or radiation for treatment of malignancies within the previous 6 months
COHORT 3: ATOPIC DERMATITIS PATIENTS: Pregnancy or lactating
History or evidence of a physician-diagnosed chronic or recurrent inflammatory skin disease (e.g. psoriasis, eczema, atopic dermatitis, hypersensitivity) at the proposed site of administration in the past 5 years.
Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.
Altered immune function, including immunodeficiency or history of immunodeficiency; eczema; history of eczema, or other eczematoid skin disorders; or those with acute, chronic or exfoliative skin conditions (e.g. atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)
The following will not be exclusionary:\r\n* Resolved ipilimumab associated inflammatory disease\r\n* The presence of laboratory evidence of autoimmune disease (e.g., positive antinuclear antibody [ANA] titer) without associated symptoms\r\n* Subjects with vitiligo, thyroiditis, or atopic dermatitis, but otherwise not meeting this criterion may be enrolled; individual cases can be discussed with the sponsor
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
The recombinant vaccinia vaccine should not be administered if the following apply to either recipients or, for at least 3 weeks after vaccination, their close household contacts (close household contacts are those who share housing or have close physical contact):\r\n* Persons with active or a history of eczema or other eczematoid skin disorders\r\n* Those with other acute, chronic or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster, severe acne or other open rashes or wounds) until condition resolves\r\n* Pregnant or nursing women; children under 3 years of age\r\n* Patients should have no evidence, as listed below, of being immunocompromised:\r\n** HIV positivity \r\n** Hepatitis B or C positivity\r\n** Concurrent use of topical steroids (including steroid eye drops) or systemic steroids; nasal or inhaled steroid use is permitted
Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
History of atopic dermatitis or active skin condition (acute, chronic, exfoliative) that disrupts the epidermis
Patients must not have active eczema, atopic dermatitis, or other exfoliative skin conditions (e.g., burns, impetigo, varicella zoster, severe acne, contact dermatitis, psoriasis, herpes or other open rashes or wounds)
Have preexisting Grade ?2 skin disorder (for example, erythema, dermatitis).
Patients must not have any of the following serious concomitant skin disorders that, in the investigator’s opinion, could interfere with assessment of EGFRI induced skin toxicity: atopic dermatitis (eczema), contact dermatitis, psoriasis, rosacea, severe photosensitivity, scleroderma, steroid-induced acne, xerosis
Presence of any active dermatological issues in radiation treatment area (i.e., fungal skin infection, dermatitis, psoriasis plaques, etc)
Individuals with any inflammation or irritation of the skin at the test area (buttocks), or any skin conditions felt by the study physician to contraindicate enrollment; this includes, but is not limited to, psoriasis or atopic dermatitis within the test area
Any dermatological condition that in the opinion of the investigator will affect the absorption of the study medication, e.g. Atopic Dermatitis, etc.
History of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment. (Parts C, D and E only).
